A phase i, first-in-human, healthy volunteer study to investigate the safety, tolerability, and pharmacokinetics of cvn424, a novel g protein-coupled receptor 6 inverse agonist for parkinson ’ s disease

HIGHLIGHTS

• who: / and collaborators from the (UNIVERSITY) have published the paper: A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson ’ s Disease, in the Journal: (JOURNAL) of September/10,/2022
• what: The authors report results of a phase first-in-human study investigating the safety tolerability and pharmacokinetics of in healthy volunteers. Based on these data, a first-in-human trial was conducted to investigate the safety, tolerability, and pharmacokinetics of CVN424 in healthy subjects. to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.